Clinical trial
Use of the MiCK Assay for Apoptosis in AML
NCT00286845 · Pierian Biosciences, Industry · Completed
Key facts
| NCT number | NCT00286845 |
|---|---|
| Title | Use of the MiCK Assay for Apoptosis in AML |
| Official title | Use of the MiCK Assay for Apoptosis to Predict Complete Remission in Acute Myeloid Leukemia |
| Lead sponsor | Pierian Biosciences, Industry |
| Collaborators | DiaTech Oncology and Vanderbilt University |
| Status | Completed |
| Study type | Observational |
| Conditions | Leukemia, Myelocytic, Acute |
| Intervention type | Drug |
| Interventions | Standard Chemotherapy |
| Enrollment | 50 |
| Start date | Jan 1, 2006 |
| Completion | Dec 1, 2009 |
| First posted | Feb 6, 2006 |
| Last update posted | Jan 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: